Summary of Purpose
To test the potential benefit of t-PA when administered within 3 hours of stroke onset.Read More →
The following dates are available for this trial. Trial information last updated on 27 May 2008.
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- National Institute for Neurological Disorders and Stroke, NIH
Randomized, double-blind trial. The trial had two parts. Part 1 (in which 291 patients were enrolled) tested whether t-PA had clinical activity, as indicated by an improvement of 4 points over base-line values in the score of the National Institutes of Health stroke scale (NIHSS) or the resolution of the neurologic deficit within 24 hours of the onset of stroke. Part 2 (in which 333 patients were enrolled) used a global test statistic to assess clinical outcome at three months, according to scores on the Barthel index, modified Rankin scale, Glasgow outcome scale, and NIHSS.